 |
 |
|
Monday 30 May 2011 |
Monday 30 May 2011 |
|
| New treatments in the management of schizophrenia – Saphris |
Recent advances in LAI antipsychotics | |
| 0730-0815 Waterfront Room 2 |
1230-1315 Waterfront Room 2 |
|
| Presenter: Professor Dieter Naber |
Presenter: Dr Andreas Schreiner |
|
| Presentation: Schizophrenia is a disabling condition that affects approximately 1% of the population worldwide. A cornerstone in the treatment of schizophrenia are antipsychotic drugs. A number of typical and atypical antipsychotics have been developed, but numerous clinical problems still exist. Such as non-adherence and insufficient chance to reach remission or recovery during long-term treatment The main determinants for choosing antipsychotic medication are efficacy and tolerability. This means effective control of the four recognized symptom domains: positive, negative, affective and cognitive symptoms. However, side-effects such as EPS, weight gain and resulting metabolic disorders, sexual dysfunction as well as sedation represent critical issues because they may override symptom-control effects and cause a patient to discontinue antipsychotic treatment. In this context, the patient’s perspective, his or her subjective quality of life has also to be seriously considered. The objective of this symposium is to review a new treatment (Asenapine) in the management of schizophrenia now available, and with reference to overseas experience, explore its place in Australian clinical practice. |
Presentation: The use of long acting injectable (LAI) antipsychotics in Australia has been ongoing since the introduction of the first typical agents onto the Australian market many decades ago. With many new agents entering the market each year the range of LAI’s available to psychiatrists continues to expand. This symposium will examine the use of LAI’s in the Australian context as well as the practical management and evidence behind the latest LAI to enter the Australian market, Invega Sustenna. |
|
 |
 |
|
Tuesday 31 May 2011 |
Tuesday 31 May 2011 |
|
| Mental illness and metabolic disease – the two headed monster | A paradigm shift in the treatment of depression | |
| 0800-0845 Waterfront Room 2 |
1230-1315 Waterfront Room 2 |
|
| Presenter: Dr Roger Chen, Endocrinologist |
Presenters: A/Prof Trevor Norman, ‘Circadian rhythmsa and depression’ Prof Philip Boyce, ‘Valdoxan clinical effectiveness’ |
|
| Presentation: Patients with schizophrenia and other severe mental illnesses (SMI) have a reduced life expectancy of 15- 20 years, largely due a significant increase in the risk of cardiovascular death. The aetiology of this excess death compared to the general population is multifactorial and includes not only genetic and lifestyle factors but also treatment and disease specific effects (1). It is clear that patients with SMI have an increased aggregation of traditional cardiovascular risk factors such as obesity, diabetes, dyslipidaemia, hypertension and smoking (2). Data from overseas and in our confirms this increase with 75% of the patients being overweight or obese and 50% with diabetes or impaired glucose tolerance. However, many patients also have limited access to general healthcare with low rates of screening and management of these modifiable risk factors (3). Antipsychotic medications can also induce weight gain and potentially worsen other risk factors such as dyslipidaemia. The advent of the second generation or atypical agents appears to have been associated with a further increase in risk of metabolic derangements. These agents are now commonly used as they are relatively free from extrapyramidal side effects and may have more favourable effects on cognitive function. However, apart from drugs, genetic or disease specific factors also need to be considered as drug naïve patients presenting with their first episode of psychosis also have an increased number of cardiovascular risk factors compared to healthy aged matched controls. This presentation will explore the interaction between these factors, which contribute to the increasing mortality gap compared to the general population. |
Presentation: Overview: For over 50 years, research into the pathophysiology of mood disorders as well as antidepressant medications, has been dominated by the monoamine hypothesis. However, it is increasingly apparent that the dysregulation of neurotransmitters is only one part of the story, and that other approaches to understanding the pathophysisiology of mood disorders should be taken into account.This symposium will focus on the paradigm shift in depression treatment that Valdoxan represents. A/Prof Norman will review the implications of circadian rhythm disturbance in depression, the evidence for Valdoxan’s proposed mode of action and practical implications for clinical use. Prof Boyce will discuss the evidence for the clinical effectiveness of Valdoxan through assessing the results from clinical trials together with Australian and international post-marketing clinical experience. |
|
|
|
|
Wednesday 1 June 2011 |
Wednesday 1 June 2011 |
|
| Balancing bipolar | Schizophrenia control and physical wellness, achievable after all? | |
| 0800-0845 Waterfront Room 2 |
1230-1315 Waterfront Room 2 |
|
| Presenters: Professor Gin Malhi Professor Phil Boyce |
Presenter: Dr Andreas Schreiner |
|
| Presentation: Bipolar disorder is a relatively common psychiatric condition characterised by intermittent episodes of mania and depression. In recent years there has been an increased public and professional awareness of the disorder, especially here in Australia. Unfortunately it is often undiagnosed or misdiagnosed in the general population and associated with high rates of suicide. Although characterised by recurrent episodes, bipolar disorder is a chronic condition associated with substantial impairment in terms of impact on the individual’s work, social and family relationships. This symposium will investigate the burden of disease associated with bipolar disorder by examining the acute and chronic management as well as the impact of the disease. |
Presentation: Much has been published on the relationship between atypicals and metabolic concerns in the treatment of schizophrenia. The treatment goal of symptom control and maintaining physical wellness appears elusive at times but is attainable. Utilising the latest clinical evidence, various treatment strategies to achieve this outcome for those living with schizophrenia will be examined. |
Home » Congress Program » Industry Supported Sessions